Organisation paid for research Program year 2021 Source: CMS Open Payments

La Biomedical Research

Neither a doctor nor a teaching hospital

Research payments

$375,241

37 payments

Through program year 2021, La Biomedical Research is reported as receiving $375,241 in research payments, across 37 payments.

By program year

3 rows
Year Kind Amount Payments
2021 Research $41,469 6
2020 Research $44,667 8
2019 Research $289,105 23

Breakdown

Who paid Research payments · program years 2019–2021
  1. AstraZeneca Pharmaceuticals LP $320,864 18 payments
  2. GlaxoSmithKline, LLC. $39,332 14 payments
  3. ViiV Healthcare Company $15,045 5 payments
Studies the money was for Research payments · program years 2019–2021
  1. A Randomized Double blind Placebo controlled two period Crossover Study to Assess the Effect of LABA LAMA therapy on Exercise Tolerance and Dynamic Hyperinflation in Patients with Chronic Obstructive Pulmonary Disease $230,213 1 payment
  2. An International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients with Preserved Ejection Fraction (HFpEF) Short Title DETERMINE-preserved Dapagliflozin EffecT on ExeRcise capacity using a 6-MINutE walk test in patients with heart failure with preserved ejection fraction $31,509 4 payments
  3. An International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients with Reduced Ejection Fraction (HFrEF) Short Title DETERMINE-reduced Dapagliflozin EffecT on ExeRcise capacity using a 6-MINutE walk test in patients with heart failure with reduced ejection fraction $26,299 6 payments
  4. A Phase IIB Randomized Double blinded Placebo controlled Parallel group Study to Evaluate the Efficacy and Safety of MEDI6570 in Participants with a Prior Myocardial Infarction Persistent Inflammation and Elevated N terminal Prohormone Brain Natriuretic Peptide $20,733 2 payments
  5. A Randomized, Double-Blind, Sponsor Open, Placebo-Controlled, 52 Week $19,832 1 payment
  6. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evalu $15,795 10 payments
  7. AMETHYST Congestive Heart Failure CHF Heart Failure Therapy Area Cardiovascular, Renal and Metabolism $11,695 2 payments
  8. A Phase Iiib, Randomized, Multicenter, Parallel-Group, Non-Inferiority $9,841 3 payments
  9. A Phase III, Randomized, Multicenter, Parallel-Group, Non-Inferiority $5,204 2 payments
  10. An Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerabil $1,900 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2021

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record